1352041-82-7

Basic information

• Product Name: C₂₀H₁₀F₆O₈
• Synonyms: C₂₀H₁₀F₆O₈
• CAS NO: 1352041-82-7
• Molecular Weight: 492.285
• Mol File: 1352041-82-7.mol

Chemical Properties

• CAS DataBase Reference: C₂₀H₁₀F₆O₈(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₁₀F₆O₈(1352041-82-7)
• EPA Substance Registry System: C₂₀H₁₀F₆O₈(1352041-82-7)

Safety Data

• Hazardous Substances Data: 1352041-82-7(Hazardous Substances Data)

Upstream product

• 627-63-4 fumaryl dichloride 

Relevant articles and documents

A novel synthetic HTB derivative, BECT inhibits lipopolysaccharide-mediated inflammatory response by suppressing the p38 MAPK/JNK and NF-κB activation pathways

Activated microglia cells are well recognized as mediators of neuroinflammation, as they release nitric oxide and pro-inflammatory cytokines in various neuroinflammatory diseases. Thus, suppressing microglial activation may alleviate neuroinflammatory and neurodegenerative processes. In the present study, we synthesized and investigated the anti-neuroinflammatory effect of a novel HTB (2-hydroxy-4-trifuoromethylbenzoic acid) derivative in lipopolysaccharide (LPS)-stimulated microglial cells. Among the synthesized derivatives, the BECT [But-2-enedioic acid bis-(2-carboxy-5-trifluoromethyl- phenyl) ester] significantly decreased production of nitric oxide and other pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1β, and interleukin-6 in microglial cells. BECT also mitigated the expression of inducible nitric oxide synthase and cyclooxygenase-2 at both the mRNA and protein levels. Further mechanistic studies demonstrated that the HTB derivative inhibited phosphorylation of JNK and p38 mitogen-activated protein kinase and nuclear translocation of nuclear factor kappa-B in LPS-stimulated BV-2 microglial cells. Thus BECT, our novel synthesized compound have anti-inflammatory activity in microglial cells, and may have therapeutic potential for treating neuroinflammatory diseases.